%0 Journal Article
%T Long-term outcomes of alternating chemoradiotherapy in patients with advanced nasopharyngeal cancer: a single-centre experience over the last decade
%A H. SATO
%A K. OMORI
%A M. IKEDA
%A M. SUZUKI
%A R. SUZUKI
%A S. SAIJOH
%A T. MATSUZUKA
%A Y. NAKAEGAWA
%J Archive of "Acta Otorhinolaryngologica Italica".
%D 2018
%R 10.14639/0392-100X-1835
%X We assessed the long-term outcomes of alternating chemoradiotherapy (ACRT) using 5-fluorouracil and cisplatin (FP) in 25 patients with stage II or advanced nasopharyngeal cancer treated at our institution between April 1999 and April 2010. Median follow-up duration was 87 months (range 2-189). According to the 2009 TNM classification (UICC), six patients were in stage II, nine in stage III, and 10 in stage IV. Treatment completion, response and five-year survival rates were retrospectively assessed. ACRT was performed with a first course of chemotherapy administered followed by the initial round of radiotherapy (36 Gy). Then, a second course of chemotherapy with additional radiotherapy (20¨C30 Gy) was administered, followed by a final third course of chemotherapy. For chemotherapy, 5-fluorouracil (5-FU, 800 mg/m2/24 h) was intravenously administered for five days, and cisplatin (CDDP, 50 mg/m2/24 h) was administered on the last two days. Treatment completion rate was 96% (24 of 25 cases), and the response rate was 100% (CR: 24 cases and PR: 1 case). Additionally, the five-year overall survival rate was 89.3%. We have demonstrated that ACRT is an effective regimen to treat nasopharyngeal cancer, revealing higher treatment completion, response, and five-year overall survival rates compared with other combinatorial radiotherapy and chemotherapy treatment regimens
%K Alternating chemoradiotherapy
%K Nasopharyngeal cancer
%K Cisplatin
%K 5-fluorouracil Chemioradioterapia alternata
%K Carcinoma del rinofaringe
%K 5-fluorouracile
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028817/